Headache News and Research

Latest Headache News and Research

Mysterious ailment, mysterious relief: Vaccines help some Covid long haulers

An estimated 10% to 30% of people who get Covid-19 suffer from lingering symptoms of the disease, or what’s known as “long Covid.”

16 Apr 2021

Recovered COVID-19 patients may need only a single vaccine dose, suggests study

People who have recovered from COVID-19 had a robust antibody response after the first mRNA vaccine dose, but little immune benefit after the second dose, according to new research from the Penn Institute of Immunology. The findings, published today in Science Immunology, suggest only a single vaccine dose may be needed to produce a sufficient antibody response.

16 Apr 2021

More than half of COVID-19 patients report persistent symptoms 12-months after infection

In a new study, appearing on the pre-print server medRxiv*, researchers at the University of Trieste and Istituto Auxologico Italiano IRCCS in Italy report that more than half of patients with previous mild-to-moderate symptomatic COVID-19 complained of the persistence of at least one symptom 12-months after the onset of the illness.

15 Apr 2021

Early monoclonal antibody therapies beneficial for COVID-19, finds study

A team of scientists recently conducted a large-scale study at Northwell Health, New York, USA, to evaluate the efficacy of neutralizing monoclonal antibody (MAB) therapies in preventing disease progression among patients with mild to moderate COVID-19. The findings reveal that the timing of initiating MAB therapy is a crucial factor in determining its efficacy against COVID-19.

14 Apr 2021

Hay fever and asthma occur earlier in life and affect more people

The unpopular guests are already here. Hazel-, alder- and elm tree pollen sweep in over us during the early spring months, with birch pollen following in May. Then grass follows in June-July before mugwort pollen closes the season in late summer. All leading to more and more people suffering.

9 Apr 2021

New Phase 1 clinical trial of investigational vaccine against B.1.351 SARS-CoV-2 variant begins

An investigational vaccine designed to protect against the B.1.351 SARS-CoV-2 variant has been administered as part of a new Phase 1 clinical trial evaluating the vaccine candidate's safety and immunogenicity in adult volunteers.

31 Mar 2021

Study finds remarkable differences in the way individuals respond to malaria

Scientists have discovered that tracking malaria as it develops in humans is a powerful way to detect how the malaria parasite causes a range of infection outcomes in its host.

31 Mar 2021

COVID-19 long haulers report persistent neurological symptoms

Researchers at Northwestern University, USA, analyzed "long hauler" patients whose symptoms lasted at least six weeks. They found persistent neurological symptoms, including brain fog and headache.

26 Mar 2021

Researchers track movements and symptoms during COVID-19 pandemic

New George Mason University College of Health and Human Services study is one of the first individual-level studies to track movements and symptoms during the COVID-19 pandemic.

26 Mar 2021

FDA approves new indication for drug to treat pediatric NDO patients

Today, the U.S. Food and Drug Administration approved a new indication for Myrbetriq (mirabegron extended-release tablets) and Myrbetriq Granules (mirabegron for extended-release oral suspension) to treat neurogenic detrusor overactivity (NDO), a bladder dysfunction related to neurological impairment, in children ages three years and older.

25 Mar 2021

What are the chief predictors of SARS-CoV-2 infection in children?

A new study seeks to explore the factors associated with the diagnosis in children. The ability to rapidly diagnose COVID-19 in this age group is essential not only for monitoring progressive disease in individual children, but to avert further transmission chains.

22 Mar 2021

New drug regimen is safe and effective in children with cystic fibrosis

An international, open-label Phase 3 study, co-led by Susanna McColley, MD, from Ann & Robert H. Lurie Children's Hospital of Chicago, found that a regimen of three drugs (elexacaftor/tezacaftor/ivacaftor) that targets the genetic cause of cystic fibrosis was safe and effective in 6-11-year-olds with at least one copy of F508del mutation in the CFTR gene, which is estimated to represent almost 90 percent of the cystic fibrosis population in the United States.

19 Mar 2021

Rare pulmonary disease discovered in rural Alberta

A rare pulmonary disease that is linked to bats has made Alberta home, according to new research led by provincial lab scientists.

19 Mar 2021

COVID-19 is more difficult to diagnose in children and adolescents, finds study

The ongoing pandemic of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread to over 192 countries and territories, causing an enormous loss of lives and economic devastation.

17 Mar 2021

New technique could enable real-time distribution monitoring of ticks that carry Lyme disease

The findings of a recent analysis conducted by the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, suggest that ecosystems suitable for harboring ticks that carry debilitating Lyme disease could be more widespread than previously thought in California, Oregon and Washington.

17 Mar 2021

Mass immunization to stop Ebola outbreak in Guinea

As the first shipment of COVID-19 vaccines arrived in Africa this week, another vaccine was being rolled out in Guinea, in a bid to stop a fresh outbreak of Ebola in its tracks.

10 Mar 2021

mRNA COVID-19 vaccines show high efficacy in pregnancy and lactation

A reassuring study reports the immunogenicity and lack of reactogenicity of the coronavirus disease 2019 (COVID-19) vaccine when given to this group of subjects. This will contribute to the sum of knowledge about the implications of vaccination in this high-risk cohort.

10 Mar 2021

Five herbal medicines show potent activity against Babesia duncani in the lab

Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the U.S., today announced the publication of new data finding that five herbal medicines had potent activity compared to commonly-used antibiotics in test tubes against Babesia duncani, a malaria-like parasite found on the West Coast of the U.S. that causes the disease babesiosis.

9 Mar 2021

Saliva testing has high accuracy in detecting early cases of SARS-CoV-2

New research finds saliva testing has a high sensitivity for detecting severe acute respiratory syndrome 2 (SARS-CoV-2) in both symptomatic and asymptomatic patients.

7 Mar 2021

Results from phase 2 trial of Novavax recombinant nanoparticle SARS-CoV-2 vaccine

Novavax, Inc., the American vaccine development company, has been developing a recombinant protein nanoparticle COVID-19 vaccine currently termed NVX-CoV2373. The full-length spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is created in a baculovirus vector, which is then inserted into a lipid nanoparticle around 50 nm in diameter.

3 Mar 2021